Journal of the American Academy of Dermatology
Response to Xue et al, "Comment on 'Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial'".
Tingting Liu, Shan Cao, Xitong Zhao, Zhenzhen Wang, Hong Liu, Furen Zhang
Published: 202610.1016/j.jaad.2026.01.031
No abstract available for this study.